Executive Director of Resource Mobilisation & Investor Relations

Founding partner and investor on behalf of the Bill & Melinda Gates Foundation.

I developed and led the Foundation's Global Health Research and Development policy, advocacy and communications strategy, as well as advocacy & policy engagement on epidemic preparedness and response.

Clients included: the UK Department for International Development (DFID), the Medicines Transparency Alliance (MeTA), the World Health Organisation (WHO), the Global Fund for HIV, TB and Malaria, Health Action International (HAI), Irish Aid, Access to Medicine Foundation, UNITAID and the International AIDS Vaccine Initiative (IAVI).Sample Projects:• Market Dynamics Evaluation of UNITAID – ‘Five Year Evaluation of UNITAID’ • Gauging demand for and guiding process toward the development of an R&D Roadmap for HIV/AIDS Vaccines - Internatonal AIDS Vaccine Alliance (IAVI)• Landscape Analysis of Vaccines Manufacturers in Emerging Markets & their Contribution to Access to Vaccines In Low & Middle Income Countries - Access To Medicine Foundation • Evaluation of Irish Aid Support to Product Development Partnerships (PDPs) – Irish Aid • Critical Review and Development of a Repository of WHO National Health Planning Tools – WHO HQ, Health Services Department, Geneva (https://extranet.who.int/nhptool/)• Review of Progress - The UK Government’s 2005 Framework for Good Practice in the Pharmaceutical Industry – UK DFID• Evaluation of Potential Impact of In-Kind Donations of Products & Services to the Global Fund (Recipient Country Survey & Board Paper) - the Global Fund to Fight AIDS, Tuberculosis & Malaria• Evaluation of National Medicines Policies and Medicine Pricing Policies in North Africa and Western Asia - WHO EMRO• Landscape Analysis of Co-Funding Models for Clinical Trials – Bioindustry Association & UK Department of Health, R&D Division

www.medicinestransparency.org International Consultant for Jordan and Technical Coordinator of the MeTA baseline pharmaceutical assessments for all seven MeTA pilot countries (Ghana, Jordan, Kyrgysztan, Peru, Philippines, Uganda and Zambia). Key Achievements: led a team on the development of framework and indicators for assessment; delivery of validated national and comparative pharmaceutical baseline data for the seven pilot countries; cross country comparative analysis; development of the MeTA toolbox http://www.medicinestransparency.org/meta-toolbox/.

Based in Geneva and Cairo, the project examined access to essential medicines by studying the legal basis for national medicine pricing policies and structure of policy-making within governments across the Eastern Mediterranean Region (EMR), which encompasses 22 countries in North Africa and Western Asia. It also examined the policies that regulate medicine price components in the pharmaceutical supply chain. A conceptual framework to assess governance structures, policies on generic medicines, details of support for local production as well as monitoring and implementation processes was formulated. The analysis and key findings were used to inform Ministries of Health in the region of the range of policies in existence and their possible effect on price and availability of medicines. Outputs were a 3 day regional workshop with key policy makers within Ministries of Health from EMR countries and consumer advocacy groups, held in Cairo in January 2007 and a briefing paper to Ministers of Health at the Regional Committee meeting in October 2007.

Led Policy work including co-drafting the UK Department of Trade and Industry (DTI) Bioscience Unit’s Biotechnology Trade and Partnerships Strategy, as well as formulating and coordinating input as the UK's representative on the EU Research Framework 6 SME Steering Committee at EuropaBio, for the duration of project with the European Commission. Responsibility for new business development, technology transfer initiatives and best practice seminars for R&D Directors and Business Development Executives. Lead the strategy and implementation of overseas sector trade missions and scientific seminars to promote business and research collaboration with the UK bioscience community. This activity included key relationship building and strategy work with UK Departments of Health and Trade and Industry, academic institutions, the Minister for Science’s Office, UK FCO Science & Technology network and global trade associations such as BIO in the US and EuropaBio in Brussels.

Research at Harvard involved several projects working with Prof. Jeffrey Sklar on human developmental protein NOTCH1, to elucidate its regulation and role in normal cell differentiation and leukaemia, as well as developing techniques for early detection of blood cancers and residual disease.